TransCode Therapeutics, Inc. (RNAZ) Stock Score, Valuation & Financial Research

TransCode Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RNAZ

TransCode Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.79. These figures are a research snapshot, not a buy or sell recommendation.

What TransCode Therapeutics, Inc. does

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

TransCode Therapeutics is a clinical-stage biopharmaceutical company that has not yet generated revenue. Its business model relies on developing and commercializing RNA-based oncology therapeutics, funded through equity offerings, strategic partnerships, and potential future licensing or collaboration agreements.

Products and services

  • The company is developing a modular RNA delivery platform, with its lead therapeutic candidate, TTX-MC138, designed to inhibit the survival of metastatic tumor cells.

Brands and product families

  • TTX platform — Proprietary delivery platform for RNA therapeutics. Source

Customer types

Oncology patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for preclinical studies, clinical trials, and the manufacturing of drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • The General Hospital Corporation (Massachusetts General Hospital) — Academic research collaboration and licensing agreement for the development of the core TTX delivery platform and therapeutic targets. Source
  • The University of Texas MD Anderson Cancer Center — Research alliance to collaborate on preclinical studies validating therapeutic and diagnostic candidates. Source

Business strengths to evaluate

  • Modular RNA delivery platform technology Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on third-party manufacturers and clinical research organizations Source

Sources: Company research source · The General Hospital Corporation (Massachusetts General Hospital) · The University of Texas MD Anderson Cancer Center

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RNAZ financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.79
Market capitalization:
1.89M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -42.78M
Free cash flow:
USD -19.52M
Cash:
USD 8.38M
Total debt:
USD 652.41K
EPS:
USD -50.69

What stands out

  • Free cash flow is USD -19.52M, negative for the stored period.
  • The balance sheet shows USD 8.38M of cash versus USD 652.41K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RNAZ

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RNAZ fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RNAZ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RNAZ to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of RNAZ's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RNAZ

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.